Interview: Nobel chemistry laureate Jennifer Doudna on the promise and peril of the genetic editing revolution
By John Mecklin,
Bulletin of the Atomic Scientists
| 12. 07. 2020
Just weeks after I interviewed her this September, UC Berkeley professor Jennifer Doudna and her colleague Emmanuelle Charpentier were jointly awarded the Nobel Prize in Chemistry for their discovery of the CRISPR/Cas9 genetic editing tool. An acronym for Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR sequences were found in bacteria, where they protect against viruses by chopping them into pieces. Doudna and Charpentier devised a way to reprogram these genetic scissors, so they could be directed to cut any DNA molecule at a predetermined site.
The CRISPR/Cas9 editing tool has greatly reduced the amount of time needed to edit genes and is now in use by researchers around the world. “There is enormous power in this genetic tool, which affects us all. It has not only revolutionized basic science, but also resulted in innovative crops and will lead to ground-breaking new medical treatments,” Claes Gustafsson, chair of the Nobel Committee for Chemistry, said in a press release accompanying the Nobel Prize announcement.
The positive potential of CRISPR editing tools is indeed breathtaking. “This tool has contributed to many important discoveries...
Related Articles
By Carl Zimmer, The New York Times | 10.20.2026
For the first time, scientists say they have used viruses designed by artificial intelligence to treat a human patient.
Researchers announced on Tuesday that they had administered the virus, known as a phage, to a patient suffering from a deadly...
By Noah Fromson, HealthLab | 10.19.2026
Gene therapy is no longer the future of medicine — it’s reality. Treatments that replace, silence or edit genes are already changing clinical care.
There are more than 6,000 rare genetic disorders but only a fraction currently have treatable targets...
By Roxanne Khamsi, The Atlantic | 10.16.2026
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to treat disease. All of these cases have one thing in common that’s not apparent...
By Rebecca Roberts, The Scientist | 10.11.2026
Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics at the end of last month.1 In the paper, Cathy Tie, the founder and chief...